文献速递系统性红斑狼疮其他结缔组织病

激活素A激活的ALK4诱导系统性红斑狼疮相关肺动脉高压中致病性Th17细胞参与的内皮-间质转化

Activin A-Activated ALK4 Induces Pathogenic Th17-Involved Endothelial-Mesenchymal Transition in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension.
PubMed 文献 · Arthritis Rheumatol · 2025-07-16

研究通过CyTOF分析发现SLE-PAH患者CD4+ T细胞减少、Th17细胞增多,血清激活素A和IL-17水平升高;激活素A经ALK4信号作用于Th17细胞和肺微血管内皮细胞,诱导IL-17分泌及内皮-间质转化,ALK4抑制剂vactosertib可改善小鼠SLE-PH。

要点

  • SLE-PAH患者Th17细胞增多,血清激活素A和IL-17水平高于单纯SLE患者和健康供者。
  • 激活素A通过ALK4信号在Th17细胞和肺微血管内皮细胞中发挥作用,诱导内皮-间质转化。
  • ALK4抑制剂vactosertib通过抑制CTGF转录有效治疗小鼠SLE-PH。

核心结论

  • 研究提示激活素A激活Th17细胞中的ALK4,诱导IL-17分泌,同时激活的ALK4通过上调CTGF在人肺微血管内皮细胞中诱导内皮-间质转化。
  • 研究提示ALK4是SLE-PAH有前景的治疗靶点。

研究设计与样本

  • 研究采用质谱流式细胞术(CyTOF)分析SLE-PAH患者中主要受影响的免疫细胞群。
  • 采用酶联免疫吸附试验测定SLE-PAH患者、SLE患者和健康供者的血清激活素A和白细胞介素-17(IL-17)水平。
  • 采用Th17细胞与肺微血管内皮细胞(PMECs)共培养及相关啮齿动物模型鉴定汇聚靶点。

主要发现

  • SLE-PAH患者经免疫抑制剂和血管扩张剂治疗后检测到CD4+ T细胞数量减少。
  • 与单纯SLE患者或供者相比,SLE-PAH患者Th17细胞群增加,血清激活素A和IL-17水平更高。
  • 激活素A在Th17细胞和PMECs中均通过激活素受体样激酶4(ALK4)传导信号。
  • 在Th17细胞中过表达ALK4可增加共培养PMECs中IL-6和内皮-间质转化(EndoMT)标志物水平。
  • 通过过表达ALK4在 mice 中诱导出严重SLE-肺动脉高压(PH),清除CD4+ T细胞的小鼠血流动力学改变减轻。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Autoimmune diseases, such as systemic lupus erythematosus (SLE), are associated with pulmonary arterial hypertension (PAH), a condition that can lead to heart failure. However, whether T cells also contribute to the occurrence of PAH in SLE has not been clarified. The objective of this study was to elucidate the role of Activin A and activated receptor signaling in SLE-PAH. METHODS: Mass Cytometry (CyTOF) analysis was performed to identify the major affected immune cell population in patients with SLE-PAH. Serum Activin A and interleukin-17 (IL-17) levels in patients with SLE-PAH, patients with SLE, and healthy donors were determined by enzyme-linked immunosorbent assay. Cocultures of Th17 cells with pulmonary microvascular endothelial cells (PMECs) and relevant rodent models were used to identify the converged target. RESULTS: The reduced CD4+ T cell number was detected in patients with SLE-PAH after treatment with immunosuppressant and vasodilator. Increased Th17 cells population and higher serum Activin A and IL-17 levels were found in patients with SLE-PAH compared to patients with SLE only or donors. Activin A signals via activin receptor-like kinase 4 (ALK4) in both Th17 cells and PMECs. Overexpressing ALK4 in Th17 cells increased IL-6 and endothelial-mesenchymal transition (EndoMT) marker levels in cocultured PMECs. We found severe SLE-pulmonary hypertension (PH) in mice by overexpressing ALK4, and alleviated hemodynamic changes in CD4+ T cells depletion mice. ALK4 inhibitor vactosertib (TEW-7197) effectively treated SLE-PH mice by repressing connective tissue growth factor (CTGF) transcription, which was induced by ALK4 activated pSmad2 and pSTAT3. CONCLUSION: Our findings suggest that Activin A activates ALK4 in Th17 cells, thereby inducing IL-17 secretion. Concurrently, activated ALK4 induces EndoMT in human PMECs (hPMECs) via CTGF up-regulation. It suggests that ALK4 is a promising therapeutic target for SLE-PAH.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Jing S, Qian J, Ying H, et al. Activin A-Activated ALK4 Induces Pathogenic Th17-Involved Endothelial-Mesenchymal Transition in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension. Arthritis Rheumatol. 2025. PMID: 40395196. doi:10.1002/art.43235

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。